The “number needed to treat” turns 20 — and continues to be used and misused

Finlay A. McAlister MD MSc

In the 20 years since the initial description of the number needed to treat, this method of expressing the efficacy of an intervention has become widely used. Indeed, the Consolidated Standards of Reporting Trials statement recommends that the number needed to treat be reported in randomized trial publications, and journals of secondary publication (e.g., American College of Physicians Journal Club) routinely calculate and report the number needed to treat for studies of therapy. As well, there have been increasing calls for health care policy makers to use numbers needed to treat to inform their recommendations; and league tables comparing numbers needed to treat have appeared in the literature and on the internet (See www.cebm.utoronto.ca/glossary/nnts.htm#table and www.jr2.ox.ac.uk/bandolier/band50/b50-8.html for examples from different branches of medicine).

Having attended hundreds of journal clubs as well as departmental and divisional rounds over the past 2 decades, I am consistently impressed by the frequency with which audience members display skepticism about a therapy if its efficacy is presented only in relative terms such as odds ratios or relative risk reductions. Not infrequently, this skepticism is healthy — the dangers of misinterpreting the importance of a therapy when relying solely on relative effect estimates are well known. However, I have also been struck by the extent to which discussions of a therapy’s number needed to treat, and even comparisons between therapies on this basis, are accepted at face value. A review of the literature and their experiences in journal club and critical appraisal settings led Chong and colleagues to also express concern that many clinicians appear to hold “the impression that NNT [number needed to treat] values in and of themselves are broadly comparable” and display “an implicit belief that an unadjusted NNT value adequately captures the overall worth of a treatment.”

In this article, I explore the factors (beyond the efficacy of a therapy) that influence the number needed to treat and that must be taken into account when comparing these values between therapies.

What is the number needed to treat?

The number needed to treat is an aggregate measure of clinical benefit that represents the number of patients who would need to be treated to prevent 1 additional adverse event. It is calculated by taking the reciprocal of the absolute risk reduction between 2 treatment options. This number is a useful way to summarize the potential impact of a therapy when discussing treatment options with patients. A detailed discussion of how to personalize this number to each patient’s situation, including means to incorporate potential harms as well as patient values and preferences, has been published.

Given the many heuristics that guide medical decision-making, it is not surprising that the number needed to treat has also been embraced by those wishing to compare 2 or more therapies. Proponents use it as though it offers a single dimensionless metric. Although the number needed to treat may appear to be an absolute measure of clinical benefit, it is in fact specific to a single comparison in a single study because it is the reciprocal of the difference in event rates between 2 treatment options. Thus, this number should not be considered in isolation. It should be viewed as specific to a particular comparison, not to a particular therapy. In addition, there are 3 other factors that can influence the number needed to treat for any therapy, above and beyond the efficacy of the therapy and the comparator.

Nontherapy factors that affect the number needed to treat

Baseline risk

Although the relative efficacy of drug therapies is often similar across patient subgroups at different risk, the number needed to treat varies inversely with baseline risk. As a re-
sult, the number needed to treat for any therapy rarely appears favourable if it is evaluated in low-risk populations. For example, although the mortality relative risk reduction with antihypertensive therapy is similar across risk strata (about 9%–12%), the number needed to treat for antihypertensive therapy to prevent 1 death over 5 years ranges from 1157 in healthy young women to 17 in older men with other cardiovascular risk factors.12

By the same token, the number needed to treat will be larger if cointerventions reduce the frequency of the outcome. For example, consider the case of a new therapy being tested for a condition for which several efficacious therapies have already become standard therapy or for which secular changes have improved the baseline risk of adverse outcomes. Because contemporary trial participants will have a lower baseline risk than those enrolled in the earlier trials, the novel therapy will always exhibit a larger number needed to treat than the earlier therapy. In early trials involving patients with myocardial infarctions, the number needed to treat for Aspirin was 42 to prevent 1 in-hospital death.13 However, if Aspirin were being tested today as a novel therapy in such patients, β-blockers, angiotensin-converting enzyme inhibitors and statins would be mandated for virtually all trial patients receiving Aspirin or placebo and the baseline mortality rate would be about 3.5%.14 As a result, the number needed to treat would at best be 124 (assuming the relative risk reduction was the same 23% as found in the earlier trials). Put another way, consider the potential impact of statins for primary prevention given the secular trends in coronary mortality seen over the past 2 decades: if statins were available in 1975, the number needed to treat to prevent 1 coronary death would have been 83 for men and 286 for women. However, in 1995, this would have been 154 for men and 1075 for women.15

**Time frame**

The number needed to treat is inherently a time-dependent measure — it depends on when the outcomes are counted. Even if the relative risk reduction from a long-term therapy is constant over time, the number needed to treat will decrease with increasing follow-up as events accrue and the absolute event rate increases. However, it is unlikely to be linear as time passes, given the increasing contribution from competing risks (i.e., other adverse outcomes not usually affected by the therapies being compared) and the use of concurrent medications that may also impact the events of interest. Of course, the relative risk reduction of a therapy is not always constant over time. In particular, surgical therapies usually involve a trade-off of early excess risk for long-term benefits.16 However, even some drug therapies demonstrate differential effects over time. In the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm (ASCOT-LLA),17 statin therapy was associated with relative reductions in coronary events (reported as hazard ratios) of 0.33 (95% confidence interval [CI] 0.14–0.78) at 90 days but only 0.64 (95% CI 0.50–0.83) at the end of the study (3.3 years). As a result, the number needed to treat to prevent a coronary event ranged from 364 patients (95% CI 210–1362) treated for 90 days to 93 patients (95% CI 59–208) treated for 3.3 years (Table 1).

Table 1: Example calculations for a trial evaluating the impact on fatal and nonfatal myocardial infarctions of statins for patients with hypertension and other cardiovascular risk factors

| Time       | Event rate in placebo arm | Event rate in intervention arm | Relative risk reduction* (95% CI) | Absolute risk reduction† (95% CI) | Number needed to treat‡ (95% CI) |
|------------|---------------------------|---------------------------------|----------------------------------|----------------------------------|----------------------------------|
| 90 d       | 21/5121                   | 7/5184                          | 0.67 (0.23–0.86)                 | 0.28 (0.07–0.48)                 | 364 (210–1362)                   |
| 12 mo      | 61/5121                   | 34/5184                          | 0.45 (0.16–0.64)                 | 0.54 (0.17–0.92)                 | 186 (109–601)                    |
| 3.3 yr (study end) | 154/5121               | 100/5184                         | 0.36 (0.18–0.50)                 | 1.08 (0.48–1.69)                 | 93 (59–208)                      |

Note: CI = confidence interval.

*Relative risk reduction = 1 – (event rate in intervention arm/event rate in placebo arm). For example, at 90 days, relative risk reduction = 1 – (7/5184) / (21/5121).
†Absolute risk reduction = event rate in placebo arm – event rate in intervention arm. For example, at 90 days, absolute risk reduction = 21/5121 – 7/5184.
‡Number needed to treat = 100/absolute risk reduction. It can also be calculated as number needed to treat = (1/absolute risk reduction) × 100. For example, at 90 days, number needed to treat = 1000.3.

CMAJ  •  SEPTEMBER 9, 2008  •  179(6)
in terms of average durations of life gained rather than focusing on differential survival at one point in the survival curve. However, a randomized trial comparing expectancy with 3.5 years of angiotensin-converting enzyme inhibition among patients with heart failure enrolled in the Studies of Left Venricular Dysfunction (SOLVD) trial as a number needed to treat of 22 to prevent 1 death over 3.5 years, it would perhaps be more informative to describe a potential gain of 1.9 months in life expectancy with 3.5 years of angiotensin-converting enzyme inhibitor treatment. However, a randomized trial comparing these 2 presentation formats proved that lay people had an easier time understanding the number needed to treat format. They were more likely to accept therapy when the benefits were expressed as the number needed to treat compared with the average duration of life gained.

Outcomes

Most therapies impact more than 1 outcome. This means that more than 1 number needed to treat that needs to be incorporated into treatment decision-making. In doing so, it takes substantial clinical experience to move beyond simple expressions of frequency. Instead, one should weigh the severity and importance of these different numbers needed to treat and integrate patient preferences. Methods to integrate efficacy and safety data from trials with each patient’s risks and values have been discussed elsewhere.

How important are these 3 factors?

This question is perhaps best answered by considering the magnitude of changes in the number needed to treat that arise if these numbers are standardized to a model population at a predefined risk with a common outcome and study duration. For example, Caro and colleagues standardized the numbers needed to treat from 18 cardiovascular trials by inputting the relative efficacy data for each therapy into simulated population models in which baseline risk, treatment duration, outcomes and comparators were standardized. They found marked changes in the numbers needed to treat after standardization ranging from a 91% decrease to a 223% increase compared to the crude numbers needed to treat reported in each trial. Importantly, the authors reported that there were no factors that could predict which crude numbers needed to treat were most likely to change markedly after standardization. This emphasizes the importance of only comparing numbers needed to treat for therapies if they have been derived against similar comparators, for the same outcome, in populations at the same stage of disease, and followed for the same duration. To the extent that any of these conditions are not met, a face-value comparison between numbers needed to treat can be misleading.

Are there other limitations?

The number needed to treat can only be expressed for binary outcomes (such as death v. survival, hospitalization v. not). It cannot be calculated for continuous outcomes, which are still relevant to patients and are frequently the intermediate targets of our therapeutic endeavours, such as changes in blood pressure, bone density or serum lipid levels. Thus, the number needed to treat may not be the best metric with which to compare chronic preventive therapies. For example, although the number needed to treat to prevent a recurrent vertebral fracture with bisphosphonate therapy was 15 in the Fracture Intervention Trial (FIT), this does not mean that 14 of every 15 patients didn’t benefit; 89% of women given bisphosphonate demonstrated at least some improvement in the bone mineral density in their lumbar spine over the first 12 months of treatment.

Although confidence intervals can be generated around the number needed to treat (by calculating the reciprocals of the confidence interval for the absolute risk reduction), it is common to see it reported as a single number, especially if the result is not statistically significant. This situation has arisen because of the difficulty in describing the confidence interval around a nonsignificant number needed to treat because it stretches between 2 values via infinity (since the reciprocal of a statistically nonsignificant absolute risk reduction, which incorporates 0, must encompass infinity). For example, a therapy exhibiting an absolute risk reduction of 10% with a 95% confidence interval of –5% to 25% would be expressed as an number needed to treat of 10 with a 95% confidence interval extending from a number needed to treat of 4 to infinity to a number needed to harm of 20. Clearly, the confidence intervals around the absolute risk reduction or the relative risk reduction are much easier to express and understand.

The number needed to treat is an expression of the frequency of an outcome event, not its utility. Patients and physicians vary their treatment decisions depending on cost, side-effect profile, ease of application, the severity of the outcome it is supposed to prevent, and personal values and preferences. Thus, a number needed to treat alone is insufficient to declare a therapy worthy of use. For example, a number needed to treat of 100 may be acceptable for a drug that is cheap, easy to take and has few side effects; however, a number needed to treat of 5 may be too high for an expensive drug that carries substantial potential toxicities.

What other factors should be considered when interpreting trial-based estimates?

Although the relative effects of many therapies are often the same in routine clinical practice as in trials (if given to comparable patients), the number needed to treat is rarely so. Generalizing a number needed to treat from a particular trial to routine care in a different setting may lead to erroneous conclusions. For example, because trial participants tend to be younger, healthier and have better prognoses (i.e., lower absolute risk) than nontrial participants, a trial-based number needed to treat may overestimate the number needed to treat for that therapy when used in clinical practice where baseline risks are higher.

On the other hand, trial-based numbers needed to treat may sometimes underestimate the numbers needed to treat in clinical practice. For example, patients in routine practice are likely to have more comorbidities than trial participants, such as...
that their risk of competing causes of death increases, thereby minimizing the potential benefits of a therapy targeting a specific mode of death (e.g., implantable cardioverter defibrillators for ventricular arrhythmias). Moreover, as patients in routine clinical practice are unlikely to take a medication under the same conditions as participants in a clinical trial (i.e., the same dose, the same intensity of monitoring by clinicians as experienced as those who participated in the trials, the same high levels of adherence, and the same low use of interventions as mandated in trial protocols), trial-based numbers needed to treat are likely to underestimate the numbers needed to treat in clinical practice.

What is the role of the number needed to treat?

Some people argue that advances in pharmacogenomics and proteomics will render the number needed to treat obsolete when we are able to personalize treatment recommendations by taking into account each patient’s biology. However, this situation is likely far in the future (and given the well-recognized pitfalls of multiple subgroup analyses, the future is perhaps not quite as rosy as it may first appear). Thus, there is clearly still a need to express the potential impacts of a therapy when discussing options with patients. The presentation of evidence about any therapy should incorporate absolute risk as well as relative benefits (and harms), and the number needed to treat remains a useful means of doing so. Methods of incorporating patient values and preferences into these discussions are familiar to experienced clinicians and formal methods of calculating numerical values such as the likelihood of being helped or harmed have been described in full elsewhere.

It is well recognized that how efficacy and safety data is presented to physicians, patients and health care policy makers influences their decisions. In fact, most studies suggest that all 3 groups make more conservative decisions about therapies when they are presented with numbers needed to treat than when they are presented with the same data presented as relative risk ratio. However, it is not entirely clear that a more conservative decision is necessarily the right one. For example, many British patients with atrial fibrillation who were likely to benefit from anticoagulant therapy because of their risk profiles and their similarity to the participants in randomized trials supporting the efficacy of warfarin declined warfarin therapy when presented with the data about their absolute risks and benefits.

This raises questions about how easy the number needed to treat is to understand, particularly since this measure is not familiar to lay people. For instance, department stores advertise sale prices in terms of relative risk reductions (e.g., “save 20% off the regular price”) or absolute risk reduction (e.g., “save $5 off the regular price”) rather than numbers needed to treat (Have any readers seen signs trumpeting “the number of discounted items that would have to be purchased to get 1 item free is X”?). Indeed, surveys of patients and medical students demonstrated that few (7% and 25% respectively) correctly interpreted the number needed to treat and could identify which treatment was most likely to be beneficial if efficacy was expressed in this way. A survey of the general public in Norway reported that although 93% of respondents consented to therapy when presented with the number needed to treat, only 35% reported that the number needed to treat was “very easy” or “somewhat easy” to understand.

The consistent finding in multiple studies that patients and physicians are insensitive to the magnitude of the number needed to treat when making treatment decisions also supports the contention that this format of expressing treatment efficacy is not as easily understood as formats such as relative or absolute risk reduction. It has been suggested that use of the “likelihood of being helped or harmed” modification of the number needed to treat (in which the ratio between the number needed to treat and the number needed to harm is adjusted for individual patient utilities and preferences) will promote understanding. However, this hypothesis that has not yet been adequately tested. Thus, for now, the most prudent course of action to maximize understanding is to continue to present information on the potential benefits from a therapy in terms of absolute risk reduction, relative risk reduction and number needed to treat. Of course, such a discussion should also include information on potential adverse effects as well as costs and inconvenience.

Final thoughts on the number needed to treat

The point of this article is not to dissuade readers from using the number needed to treat when discussing treatment options with their patients. This measure remains a valuable tool in our efforts to improve communication with patients at the bedside and in the office. However, I hope to remind readers that numbers needed to treat for different therapies can only be compared if the therapies were tested in similar populations with the same condition (and preferably at the same stage of disease), for their effects on the same outcomes, against the same comparator and over the same time frame. To the extent that these conditions are not met, comparisons based on numbers needed to treat may be misleading. The words of the editors of Bandolier (in a footnote which frequently accompanies number needed to treat league tables provided on their evidence-based medicine website) are worth remembering: numbers needed to treat “are reproduced here with a simple health warning — that readers should always go back to original papers to get all the nuances of the original studies.”

This article has been peer reviewed.

Competing interests: None declared.

Acknowledgements: I thank Drs. Andreas Laupacis, David Sackett and Donald Redelmeier for their insights on earlier versions of this manuscript.

Dr. McAlister receives salary support from the Canadian Institutes of Health Research and the Alberta Heritage Foundation for Medical Research. He holds the Merck Frosst/Aventis Chair in Patient Health Management at the University of Alberta.
REFERENCES

1. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988;318:1728-33.
2. Moher D, Schulz TF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285:1987-91,9-30.
3. Muir Gray JA. Evidence-based healthcare: how to make health policy and management decisions. Edinburgh: Churchill Livingstone, 1997.
4. Kumana CR, Cheung BMY, Lauder I. Gauging the impact of statins using number needed to treat. JAMA 1999;282:1899-901.
5. Osiu M, Suarez-Almazor ME, Wells GA, et al. Number needed to treat (NNT): implications in rheumatology clinical practice. Ann Rheum Dis 2003;62:316-21.
6. Huyyn NT, Rompré PH, Montplaisir JY, et al. Comparison of various treatments for sleep bruxism using determinants of number needed to treat and effect size. Int J Prosthodont 2006;19:439-41.
7. Otterstad JE, Slettig F. The HOPE study: comparison with other trials of secondary prevention. Ear Heart J 2001;22:1307-10.
8. Chong CAY, Tomlinson G, Chudirker L, et al. An unadjusted NNT was a moderately good predictor of health benefit. J Clin Epidemiol 2006;59:224-33.
9. McAlister FA, Strauss SE, Haynes RB, et al.; Evidence-based Medicine Working Group. Users’ guides to the medical literature: XX. Integrating research evidence with the care of the individual patient. JAMA 2000;283:2829-36.
10. Alter DA, Manuel DG, Gunraj N, et al. Age, risk-benefit trade-offs, and the projected effects of evidence-based therapies. Am J Med 2004;116:540-5.
11. McAlister FA. Relative treatment effects are consistent across a spectrum of underlying risks…usually. Int J Epidemiol 2002;31:76-7.
12. Guyerfi F, Besissou JP, Besissou JP, et al. Effect of antiplatelet therapy on cardiovascular outcomes in women and men. A meta-analysis of individual participant data from randomized, controlled trials. Ann Intern Med 1997;126:761-7.
13. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
14. Fox KA, Steg PG, Eagle KA, et al. GRACE Investigators. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA 2007;297:1892-900.
15. Smeeth L, Haines A, Ebrahim S. Numbers needed to treat derived from meta-analyses – sometimes informative, usually misleading. BMJ 1999;318:1548-51.
16. Rothwell PM, Eliasziw M, Gutnikov SA, et al.; Carotid Endarterectomy Trialists’ Collaborative. Influence of inclusion criteria on estimates for improving the quality of reports of parallel-group randomized trials. J Intern Med 2000;248:45-8.
17. Sever PS, Elashuw M, Gnutikov SA, et al.; Carotid Endarterectomy Trialists’ Collaborative. Analysis of pooled data from the randomized controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet 2003;361:107-16.
18. Sever PS, Poulter NR, Dohloth B, et al. Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Eur Heart J 2004;25:1757-9.
19. Tan LB, Murphy R. Shifts in mortality curves: Saving or extending lives? Am J Med 2003;116:540-5.
20. Lubsen J, Hoes A, Grohee D. Implications of number needed to treat, costs and outcomes on preferences for a preventive drug. Value Health 2004;7:585-94.
21. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991;325:293-302.
22. Torp-Pedersen C, Kober L for The Trandolapril Cardiac Evaluation Study Group. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. Lancet 1999;354:9-12.
23. Halvorsen PA, Selmer R, Kristiansen IS. Different ways to describe the benefits of risk-reducing treatments. A randomized trial. Int J Epidemiol 2007;36:848-56.
24. Caro JJ, Ishak KJ, Caro J, et al. Comparing medications in a therapeutic area using an NNT model. Value Health 2004;7:585-94.
25. Christensen PM, Kristiansen IS. Number needed to treat (NNT) — Needs treatment with care. Basic Clin Pharmacol Toxicol 2006;99:12-6.
26. Hochberg MC, Ross PD, Black D, et al.; Fracture Intervention Trial Research Group. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum 1999;42:1246-54.
27. Altman DG. Confidence intervals for the number needed to treat. BMJ 1998;317:1309-12.
28. McAlister FA, O’Connor AM, Wells G, et al. When should hypertension be treated? The different perspectives of Canadian patients and family physicians. CMAJ 2000;163:383-8.
29. Halvorsen PA, Kristiansen IS. Decisions on drug therapies by number needed to treat: a randomized trial. Arch Intern Med 2005;165:1140-6.
30. Nexo E, Kristiansen IS, Gyhr-Hansen D, et al. Influence of number needed to treat, costs and outcomes on preferences for a preventive drug. Fam Pract 2005;22:126-31.
31. Vist GE, Hagen KB, Devevero PJ, et al. Systematic review to determine whether participation in a trials influence outcomes. BMJ 2005;330:1175.
32. Gross CP, Krumholz HM, Van Wye G, et al. Does random treatment assignment cause harm to research participants? PLoS Med 2006;3:e188.
33. McAlister FA. Applying evidence to patient care: from black and white to shades of grey. Arch Intern Med 2003;163:938-9.
34. Kent DM, Alsheikh-Ali A, Hayward RA. Competing risk and heterogeneity of treatment effect in clinical trials. Trials 2008;9:30.
35. Assmann SF, Pocock SJ, Enos LE, et al. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000;355:1064-9.
36. Straus SE. Individualizing treatment decisions. The likelihood of being helped or harmed. CMAJ 2002;25:210-7.
37. Naylor CD, Chen E, Straus B. Measured enthusiasm: Does the method of reporting trial results alter perceptions of therapeutic effectiveness? Ann Intern Med 1992;117:916-21.
38. Foreen L, Taylor WC, Arnold RM. Absolutely relative: how research results are summarized can affect treatment decisions. Am J Med 1992;92:121-4.
39. Huix JE, Naylor CD. Communicating the benefits of chronic preventative therapy: Does the format of efficacy data determine patients’ acceptance of treatment? Med Decis Making 1995;15:152-7.
40. Cranney A, Walleys T. Same information, different decisions: the influence of evidence on the management of hypertension in the elderly. Br J Gen Pract 1996;46:661-3.
41. Bacher HC, Weinbacher M, Gy K. Influence of method of reporting study results on decision of physicians to prescribe drugs to lower cholesterol concentration. BMJ 1994;309:761-4.
42. Protheroe J, Faiyer T, Montgomery AA, et al. The impact of patients’ preferences in the treatment of atrial fibrillation: observational study of patient-based decision analysis. BMJ 2000;320:1380-4.
43. Sheridan SL, Pignone MP, Numercy M. The medical student’s ability to interpret data. Eff Clin Pract 2002;5:35-40.
44. Sheridan SL, Pignone MP, Lewis CL. A randomized comparison of patients’ understanding of number needed to treat and other common risk reduction formats. J Gen Intern Med 2003;18:884-92.
45. Kristiansen IS, Gyhr-Hansen D, Nexo E, et al. Number needed to treat: Easily understood and intuitively meaningful? Theoretical considerations and a randomized trial. J Clin Epidemiol 2002;55:888-92.
46. Bandolier: evidence based thinking about health care. Available: www.medicine.ox.ac.uk/bandolier/band17/b17-7.html (accessed 2008 July 21).

Correspondence to: Dr. Finlay McAlister, 2E3-24 WMC, University of Alberta Hospital, 8440 112 St., Edmonton AB T6G 2R7; fax: 780-407-2680; Finlay.McAlister@ualberta.ca

Abdominal Aortic Aneurysm (AAA) Screening

The Canadian Society for Vascular Surgery (CSVS) is calling for a national screening program for AAA.

AAA is a common, silent and treatable disorder.

Five per cent of men over the age of 65 have an AAA.

Current medical evidence demonstrates that a focused abdominal AAA screening ultrasound in men will reduce AAA related mortality by half.

The CSVS recommends:

• An ultrasound screening for men 65 to 75 years of age.
• A Selective screening of high risk populations, such as men under 65 with a family history; and
• A women over 65 with a history of smoking, cerebrovascular disease and family AAA.

The USA and the UK have screening programs. It is time for Canada to take action.

For more information see http://csvs.vascularweb.org